

# Type 2 diabetes self-management using continuous glucose monitoring

<b>Submission date</b> 16/04/2021	<b>Recruitment status</b> No longer recruiting	<input checked="" type="checkbox"/> Prospectively registered <input type="checkbox"/> Protocol
<b>Registration date</b> 22/04/2021	<b>Overall study status</b> Completed	<input type="checkbox"/> Statistical analysis plan <input checked="" type="checkbox"/> Results
<b>Last Edited</b> 26/08/2025	<b>Condition category</b> Nutritional, Metabolic, Endocrine	<input type="checkbox"/> Individual participant data

## Plain English summary of protocol

### Background and study aims

People living with diabetes are required to self-manage their condition through a variety of self-care activities such as eating a healthy diet, exercising regularly, taking medication, and monitoring their blood glucose levels. Individuals living with Type 2 Diabetes who receive support from specialist diabetes teams typically have complex health care needs and multiple chronic conditions for them to self-manage. This requires continuous effort and can be physically, emotionally, intellectually, and socially demanding.

Continuous glucose monitors (CGM) have been developed to give people with diabetes real-time readings of their blood glucose levels. It has been shown that using CGM can help some people with diabetes manage their blood glucose levels and improve their quality of life.

The aim of the study is to determine whether being able to see blood glucose levels using CGM for 12 weeks will help support people with complex Type 2 Diabetes to self-manage their diabetes.

### Who can participate?

Adults with established Type 2 Diabetes (for over 1 year) and under the care of specialist hospital diabetes teams (Outpatients) will be invited to take part.

### What does the study involve?

The study will compare the short-term use (12 weeks) of CGM on self-management behaviour compared to usual care. All participants will use a continuous glucose monitor as part of the study. Participants will be asked to attend 6 study visits over 36 weeks and will also receive 2 phone calls from the study nurse during the 12 week period that they are using the CGM device.

Participants will be allocated to receive either CGM or usual care for 12 weeks, with an equal chance of being in either group (like tossing a coin) for the first period of the study. In the second period of the study, participants will receive the intervention that they did not receive in the first half of the study. In the third 12 week period of the study, no participants will have access to the CGM device.

Participants will wear the CGM device for 3 separate periods throughout the study. Two of the periods will last for 10 days each and during this time the participant will not be able to see their

blood glucose readings. The third period will last for 12 weeks when the participant will be able to use the CGM device fully to help them self-manage their diabetes. All participants will wear the CGM device for 12 weeks followed by a period of 12 weeks when they will receive usual care and not wear the device.

Throughout the study participants will be asked to complete the following questionnaires:

1. Diabetes Self-Management Questionnaire at randomisation, 12, 24 & 36 weeks;
2. Patient Activation Measure at screening, randomisation, 12, 24 & 36 weeks;
3. Audit of Diabetes Dependent Quality of Life Questionnaire at randomisation, 12, 24 & 36 weeks;
4. Problem Areas in Diabetes (PAID-5) questionnaire at randomisation, 12, 24 & 36 weeks.

The clinical measurements of HbA1c (glycated haemoglobin, which is a marker from blood samples of how well-controlled blood sugar has been the previous few months), total cholesterol, weight, BMI, and waist circumference will also be recorded.

What are the possible benefits and risks of participating?

The aim of the study is to determine whether CGM can help support people with complex Type 2 Diabetes manage their diabetes so possible benefits of taking part in the study could include a better understanding of Type 2 Diabetes, an improvement in diabetes self-management skills, an improvement in diabetes-related quality of life, and a reduction in diabetes-related distress. There could also be an improvement in an individual's blood glucose control and other clinical outcomes such as weight, reducing their risk of developing the complications of diabetes.

However, there may be no clinical benefit to taking part in the study and the use of a continuous glucose monitor may result in some discomfort, irritation, and redness at the site where the sensor is inserted. It may also increase anxiety or diabetes-related distress by providing regular blood glucose readings. Blood samples will be taken as part of the study which may cause some discomfort or bruising, however, this does not usually cause serious problems.

Where is the study run from?

Diabetes Research Group, Swansea University (UK)

When is the study starting and how long is it expected to run for?

From May 2020 to March 2023 (updated 25/05/2022, previously: February 2023; updated 31/03/2022, previously: December 2022; updated 19/10/2021, previously: August 2022; updated 03/08/2021, previously: July 2022)

Who is funding the study?

Dexcom (USA) and Swansea University (UK)

Who is the main contact?

Dr Sharon Parsons

S.N.Parsons@Swansea.ac.uk

## Contact information

Type(s)

Public

Contact name

Dr Sharon Parsons

### **ORCID ID**

<https://orcid.org/0000-0002-5841-8309>

### **Contact details**

Diabetes Research Group  
Swansea University  
Grove Building  
Singleton Park  
Swansea  
United Kingdom  
SA2 8PP  
+44 (0)1792 606721  
S.N.Parsons@Swansea.ac.uk

## **Additional identifiers**

### **Clinical Trials Information System (CTIS)**

Nil known

### **Integrated Research Application System (IRAS)**

290957

### **Protocol serial number**

IRAS 290957, RIO 031-20

## **Study information**

### **Scientific Title**

A randomised, controlled crossover study of short-term use of continuous glucose monitoring (CGM) to support self-management behaviour in complex type 2 diabetes mellitus: the DISCO GM study

### **Acronym**

DISCO GM

### **Study objectives**

Visualisation of blood glucose levels through the short-term use of continuous glucose monitoring alters self-management behaviour in people with complex type 2 diabetes mellitus.

### **Ethics approval required**

Old ethics approval format

### **Ethics approval(s)**

Approved 12/01/2021, Wales Rec 6 (Public Health Wales, Building 1, Jobswell Road, St David's Park, SA31 3HB; +44 (0)1267 611164; Wales.REC6@Wales.nhs.uk), ref: 20/WA/0349

### **Study design**

Single centre interventional randomized crossover trial

## Primary study design

Interventional

## Study type(s)

Treatment

## Health condition(s) or problem(s) studied

Self-management of type 2 diabetes

## Interventions

The study will be a randomised controlled crossover study of 36 weeks duration comparing:

1. Routine diabetes care plus diabetes self-management education
2. Short term use of Continuous Glucose Monitoring (12 weeks) plus diabetes self-management education.

Following diabetes self-management education, each participant will be randomised to undertake each intervention for a period of 12 weeks, followed by a 12-week follow-up period. The treatment sequence will be allocated at random. Randomisation will be performed using a computer generated list of random study sequence. Participants will be stratified according to whether they receive insulin therapy.

## Intervention Type

Device

## Phase

Not Applicable

## Drug/device/biological/vaccine name(s)

Not provided at time of registration

## Primary outcome(s)

Diabetes self-management behaviour will be measured using the Diabetes Self-Management Questionnaire (DSMQ) at randomisation, 12, 24, and 36 weeks.

## Key secondary outcome(s)

1. Diabetes-related quality of life measured using the Audit of Diabetes Dependent Quality of Life (ADDQoL) questionnaire at randomisation, 12, 24, and 36 weeks
2. Diabetes related distress measured using the Problem Areas in Diabetes (PAID-5) questionnaire at randomisation, 12, 24, and 36 weeks.
3. Patient Activation Level measured using the Patient Activation Measure (PAM) at screening, randomisation, 12, 24, and 36 weeks
4. Blood glucose control measured using HbA1c at randomisation, 12, 24, and 36 weeks
5. Glucose variability, incidence of hypoglycaemia, and time in range metrics will be measured using the continuous glucose monitoring device during the 12 week period the participant wears the device
6. Clinical outcomes such as weight, BMI, waist circumference and total cholesterol will be measured at randomisation, 12, 24 and 36 weeks

## Completion date

31/03/2023

# Eligibility

## Key inclusion criteria

1. Aged over 18 years
2. Diagnosed with Type 2 Diabetes for over 1 year
3. Receiving care from a specialist diabetes team (hospital outpatient setting)
4. HbA1c level equal to or over 75 mmol/mol (9%)
5. Willing and able to provide informed consent
6. Willing and able to engage with continuous glucose monitoring

## Participant type(s)

Patient

## Healthy volunteers allowed

No

## Age group

Adult

## Lower age limit

18 years

## Sex

All

## Total final enrolment

62

## Key exclusion criteria

1. Diabetes other than Type 2 Diabetes
2. Pregnancy
3. Participation in any investigational drug trial within one month prior to visit 1
4. Condition rendering the participant unable to understand the nature, scope, and possible consequences of the study
5. End-stage renal disease (existing or planned dialysis or transplantation)
6. Severe non-proliferative diabetic retinopathy, proliferative diabetic retinopathy, and diabetic macular oedema
7. Blindness or severe loss of visual acuity in both eyes
8. Treatment with hydroxyurea
9. Treatment with paracetamol (acetaminophen) higher than 1,000 mg every 6 h daily

## Date of first enrolment

21/06/2021

## Date of final enrolment

30/06/2022

# Locations

**Countries of recruitment**

United Kingdom

Wales

**Study participating centre**

**Clinical Research Unit, Morriston Hospital**

Heol Maes Eglwys

Swansea

United Kingdom

SA6 6NL

**Sponsor information****Organisation**

Swansea University

**ROR**

<https://ror.org/053fq8t95>

**Funder(s)****Funder type**

Industry

**Funder Name**

Dexcom

**Alternative Name(s)**

Dexcom, Inc.

**Funding Body Type**

Government organisation

**Funding Body Subtype**

For-profit companies (industry)

**Location**

United States of America

**Funder Name**

Swansea University

**Alternative Name(s)**

, Prifysgol Abertawe

**Funding Body Type**

Government organisation

**Funding Body Subtype**

Universities (academic only)

**Location**

United Kingdom

## Results and Publications

**Individual participant data (IPD) sharing plan**

The datasets generated during and/or analysed during the current study will be available upon request from Dr Sharon Parsons (S.N.Parsons@Swansea.ac.uk) once all analysis and study publications have been completed. All data shared will be anonymised and released following review of the request and agreement by the Chief Investigator and all Co-Investigators

**IPD sharing plan summary**

Available on request

**Study outputs**

Output type	Details	Date created	Date added	Peer reviewed?	Patient-facing?
<a href="#">Results article</a>		14/08/2025	26/08/2025	Yes	No
<a href="#">HRA research summary</a>			28/06/2023	No	No